GSK 1482160
Alternative Names: 1482160; GSK1482160Latest Information Update: 18 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-inflammatories
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammatory-pain(In volunteers) in United Kingdom (PO)
- 30 Nov 2008 Phase-I clinical trials in Inflammatory pain in United Kingdom (PO)